Effect of periprocedural furosemide-induced diuresis with matched isotonic intravenous hydration in patients with chronic kidney disease undergoing transcatheter aortic valve implantation.

Lisa Voigtländer-Buschmann,Sarina Schäfer,Christian Schmidt-Lauber,Jessica Weimann,Mina Shenas,Julian Giraldo Cortes,Piotr Mariusz Kuta,Tanja Zeller,Raphael Twerenbold,Moritz Seiffert,Niklas Schofer,Yvonne Schneeberger,Andreas Schäfer,Johannes Schirmer,Hermann Reichenspurner,Stefan Blankenberg,Lenard Conradi,Ulrich Schäfer

Clinical research in cardiology : official journal of the German Cardiac Society（2023）

引用 0|浏览5

暂无评分

摘要

In this randomized trial, we did not detect a reduction in AKI after TAVI by using the RenalGuard system. A substantial number of patients with chronic kidney disease developed AKI after TAVI, whereas the majority presented with mild AKI according to stage 1 (ClinicalTrials.gov number NCT04537325).

查看译文

关键词

Transcatheter aortic valve implantation, Acute kidney injury, RenalGuard, Chronic kidney disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要